HELF AI Initiates Phase 1 Beta Testing

HELF AI to Launch Phase 1 of Beta Testing for Innovative Healthcare AI Platform

SINGAPORE, May 18, 2024 /EINPresswire.com/ -- HELF, an emerging leader in healthcare AI, announces the upcoming launch of Phase 1 beta testing for its revolutionary AI-powered healthcare platform, set to commence in just two weeks. This initial phase seeks 10–30 healthcare professionals to participate, with overflow applicants automatically qualifying for Phase 2.

"The platform is designed to utilize AI to assist healthcare professionals and contribute to improved patient outcomes," says Dr. Reid Lim, AI visionary and founder of HELF. "Your insights during this beta test are crucial. By joining us, you'll play a pivotal role in shaping the future of healthcare, making it smarter, safer, and more accessible for all."

In a market increasingly driven by AI solutions, HELF's platform is designed to significantly enhance global healthcare standards. It provides access to the latest medical research findings, empowering health professionals with the most up-to-date knowledge to make informed clinical decisions and improve patient outcomes.

HELF'S LOGO

HELF1

what is the latest data on when to use to ticagrelor and when to use clopidogrel?

HELF1

Key Insights:

1. Ticagrelor vs. Clopidogrel in Patients with Chronic Kidney Disease (CKD) and Cardiovascular Disease:

- A meta-analysis compared the use of ticagrelor and clopidogrel in CKD patients with cardiovascular disease.
- The study found no significant differences in major adverse cardiac events (MACEs), all-cause mortality, cardiovascular death, myocardial infarction, ischemic stroke, and hemorrhagic stroke between the two drugs.
- Ticagrelor was associated with significantly higher bleeding events compared to clopidogrel.
- The study suggests the need for further evaluation of ticagrelor's safety in CKD patients.
- Read more

2. Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes:

- The review discusses the use of antiplatelet therapy in older patients with ACS.
- It suggests a de-escalation strategy in high bleeding risk patients, starting with aspirin and low-dose prasugrel and switching t aspirin and clopidogrel after 2-3 months.
- The review emphasizes the importance of tailoring antiplatelet treatment based on individual thrombotic and bleeding risks.

A User's Question Answered by HELF, the AI Health Assistant.

Be Part of the Healthcare Revolution
Registration and Participation

The Phase 1 beta test is designed to gather invaluable feedback from healthcare professionals on the platform's functionalities and user experience, ultimately optimizing it for real-world applications.

Participation in the beta test is entirely free and requires no prior registration. Interested healthcare professionals can simply register using the following link: sign up for HELF Beta Testing.

Upon the official launch of HELF Beta, participants will receive detailed instructions via email to begin their experience with the platform.

About HELF

HELF (Health Expert Language Framework) is a healthcare AI platform founded by a Singaporean medical doctor. Committed to leveraging the power of AI to improve healthcare, HELF develops innovative and accessible solutions that address the most pressing challenges in healthcare today.

Stella Orji
HELF
+65 8941 9311
admin@helf.co
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/712475004